This work is part of the research conducted at the Department of Pharmaceutical Chemistry, University of Zagreb Faculty of Pharmacy and Biochemistry, within the project Role of Transthyretin in Leptomeningeal and Cerebrovascular Amyloidosis Associated with Sporadic Alzheimer's Disease and the Neuroprotective Potential of Tafamidis Prodrug – TransADamis of the School of Medicine, University of Zagreb, which encompasses the synthesis and in vivo testing of the ability of the amide prodrug of tafamidis to stabilize transthyretin (TTR) in the central nervous system and mitigate streptozotocin-induced neurodegeneration and cognitive deficit. The aim of this thesis was the synthesis and characterization of the amide prodrug of tafamidis. The synthesis began with the conversion of tafamidis carboxylic acid to the corresponding piperazine amide 1 with a tert-butoxycarbonyl protecting group, followed by hydrolysis of the protecting group to obtain the final product 2. The structures of all synthesized compounds were confirmed by standard analytical and spectroscopic methods (FT-IR, 1H and 13C NMR, MS), and the relative purity was determined by high-performance liquid chromatography (HPLC). The final product fully complies with Lipinski's and Veber's rules used to predict the oral bioavailability of drugs. Additionally, the web tool SwissADME predicts high oral bioavailability and the ability of amide 2 to cross the blood-brain barrier, which is consistent with the results of a previously published in vivo study. The effect of amide 2 on the stabilization of TTR in the central nervous system and the mitigation of neurodegeneration will be examined in further research beyond the scope of this paper.